Home/Filings/4/0000899243-17-029679
4//SEC Filing

Rozenman Mary M. 4

Accession 0000899243-17-029679

CIK 0001631650other

Filed

Dec 27, 7:00 PM ET

Accepted

Dec 28, 5:45 PM ET

Size

36.1 KB

Accession

0000899243-17-029679

Insider Transaction Report

Form 4
Period: 2017-12-26
Rozenman Mary M.
See Remarks
Transactions
  • Sale

    Common Stock, $0.0001 par value

    2017-12-26$38.83/sh11,000$427,11539,139 total
  • Sale

    Common Stock, $0.0001 par value

    2017-12-26$39.23/sh1,500$58,84725,139 total
  • Sale

    Common Stock, $0.0001 par value

    2017-12-26$38.80/sh4,310$167,23920,829 total
  • Sale

    Common Stock, $0.0001 par value

    2017-12-26$39.28/sh1,200$47,13410,129 total
  • Exercise/Conversion

    Common Stock, $0.0001 par value

    2017-12-26$3.02/sh+75,010$226,68075,139 total
  • Sale

    Common Stock, $0.0001 par value

    2017-12-26$39.23/sh1,800$70,60550,139 total
  • Sale

    Common Stock, $0.0001 par value

    2017-12-26$38.82/sh10,700$415,32251,939 total
  • Sale

    Common Stock, $0.0001 par value

    2017-12-26$39.26/sh700$27,47920,129 total
  • Sale

    Common Stock, $0.0001 par value

    2017-12-26$38.73/sh6,400$247,8483,729 total
  • Sale

    Common Stock, $0.0001 par value

    2017-12-26$38.83/sh11,000$427,08964,139 total
  • Sale

    Common Stock, $0.0001 par value

    2017-12-26$39.25/sh1,500$58,87862,639 total
  • Sale

    Common Stock, $0.0001 par value

    2017-12-26$39.25/sh1,500$58,87537,639 total
  • Sale

    Common Stock, $0.0001 par value

    2017-12-26$38.82/sh11,000$427,04326,639 total
  • Sale

    Common Stock, $0.0001 par value

    2017-12-26$38.83/sh8,800$341,66311,329 total
  • Sale

    Common Stock, $0.0001 par value

    2017-12-26$39.15/sh3,600$140,949129 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2017-12-2675,010120,426 total
    Exercise: $3.02Exp: 2025-04-17Common Stock (75,010 underlying)
Footnotes (15)
  • [F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
  • [F10]The transaction was executed in multiple trades in prices ranging from $39.15 to $39.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F11]The transaction was executed in multiple trades in prices ranging from $38.15 to $39.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F12]The transaction was executed in multiple trades in prices ranging from $39.16 to $39.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F13]The transaction was executed in multiple trades in prices ranging from $38.06 to $39.06, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F14]The transaction was executed in multiple trades in prices ranging from $39.07 to $39.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F15]The option is immediately exercisable in full or in part. The shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest on the first anniversary measured from February 1, 2015 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
  • [F2]The transaction was executed in multiple trades in prices ranging from $38.13 to $39.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F3]The transaction was executed in multiple trades in prices ranging from $39.14 to $39.41, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F4]The transaction was executed in multiple trades in prices ranging from $39.14 to $39.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F5]The transaction was executed in multiple trades in prices ranging from $38.14 to $39.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F6]The transaction was executed in multiple trades in prices ranging from $39.15 to $39.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F7]The transaction was executed in multiple trades in prices ranging from $38.12 to $39.12, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F8]The transaction was executed in multiple trades in prices ranging from $39.13 to $39.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F9]The transaction was executed in multiple trades in prices ranging from $38.14 to $39.12, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.

Issuer

Aimmune Therapeutics, Inc.

CIK 0001631650

Entity typeother

Related Parties

1
  • filerCIK 0001648920

Filing Metadata

Form type
4
Filed
Dec 27, 7:00 PM ET
Accepted
Dec 28, 5:45 PM ET
Size
36.1 KB